Prevnar

Type: Product
Name: Prevnar
First reported Apr 09 2014 - Updated Apr 09 2014 - 1 reports

Pfizer: It Never Rains, It Pours

SummaryPfizer has been beaten up these past two days. It was cheap before, now it is cheaper. The stock maybe of interest to value investors. The company offers a dividend yield of 3.2% and the dividend can grow at a long term rate of 5% to 6%. This ... [Published Seeking Alpha - Apr 09 2014]
First reported Mar 26 2014 - Updated Mar 27 2014 - 3 reports

Pfizer Local Partnership Opens Door To Russia Purchase Of Vaccine

Article # 28140327004Posted: Mar. 27, 2014 6:50 AM GMTExecutive SummaryPfizer has expectations that Russia's government will favor its partnership with Pretrovax , a local partner, and agree to buy the U.S. company's Prevenar 13 vaccine against pneumonia ... [Published Health News Daily - Mar 27 2014]
Entities: Pfizer Inc, Vaccine, Russia
First reported Mar 27 2014 - Updated Mar 27 2014 - 1 reports

Parents invited to observe at FPS, register students during roundup

Fredericksburg Primary School is inviting the parents of four- and five-year-olds to visit the campus to check out its operations and then return later to register their children for next year.Prospective students’ parents may observe pre-kindergarten ... [Published Fredericksburg Standard Post - Mar 27 2014]
First reported Mar 25 2014 - Updated Mar 25 2014 - 1 reports

Five Star Stock Watch: Pfizer

If traders have been paying much attention to the market at all the past couple of days, then they know biotech and/or pharmaceutical stocks have been getting hit hard.Some of the highest flyers such as PCRX, ISIS and INCY have taken it pretty good, but ... [Published Benzinga.com - Mar 25 2014]
First reported Mar 24 2014 - Updated Mar 24 2014 - 1 reports

Renaissance Technologies buys a stake in Pfizer in 4Q13

Renaissance Technologies' 4Q13 positions in Disney and more (Part 4 of 7)( Continued from Part 3 )Renaissance Technologies and PfizerThe New York–based quant hedge fund Renaissance Technologies initiated positions in Pfizer Inc. (PFE), AT&T Inc. (T), ... [Published Yahoo! Finance - Mar 24 2014]
First reported Mar 24 2014 - Updated Mar 24 2014 - 2 reports

Breakthrough Therapy Status for Pfizer's Drug - Analyst Blog

Breakthrough Therapy designation is a status provided under the Food and Drug Administration Safety and Innovation Act (FDASIA) of 2012 to potential candidates that show superiority over existing therapies for the treatment of serious or life threatening ... [Published Zacks.com - Mar 24 2014]
First reported Mar 20 2014 - Updated Mar 21 2014 - 1 reports

Pfizer snags a 'breakthrough' tag for its meningitis vaccine in a race with Novartis

Pfizer ($PFE) picked up the FDA's breakthrough therapy designation for an in-development vaccine against meningococcal disease, a common cause of meningitis, lighting the path for an accelerated approval as the drugmaker looks to expand its vaccine portfolio ... [Published FierceBiotech - Mar 20 2014]
First reported Mar 20 2014 - Updated Mar 21 2014 - 1 reports

Sanofi launches a vaccine R&D program with blockbuster Prevnar 13 in its sights

Sanofi has put Pfizer ($PFE) on notice that it's going after the blockbuster pneumococcal conjugate vaccine market and Prevnar 13. France's pharma giant is partnering with SK Chemicals in South Korea to ramp up a global vaccine program, kicking off with ... [Published FierceBiotech - Mar 20 2014]
Entities: Sanofi SA, Prevnar, Vaccine
First reported Mar 20 2014 - Updated Mar 20 2014 - 2 reports

Recent Trials Could Help Pfizer Solidify Its Dominance In Pneumococcal Vaccine Market

By Trefis :Recent trials for Pfizer ’s ( PFE ) Prevnar 13 vaccine showed encouraging results and could potentially boost the franchise’s sales going forward. The vaccine is useful for people who are at higher risk of contracting pneumococcal diseases ... [Published BioPortfolio - Mar 20 2014]
First reported Mar 19 2014 - Updated Mar 20 2014 - 2 reports

Why Pfizer's Debt Levels Should Be Of Little Concern

By FAF Research :Over the past few weeks I have been watching the developments of the pharmaceutical industry, which has provided an excellent opportunity to search for investment stocks in this sector. One company I think is very interesting to analyze ... [Published BioPortfolio - Mar 19 2014]
First reported Mar 19 2014 - Updated Mar 19 2014 - 1 reports

Mixed News for Pfizer: A Good Chance to Buy?

Last week was unusually eventful for Pfizer ( NYSE: PFE     ) . The company, along with partner Bristol-Myers Squibb ( NYSE: BMY     ) won a supplementary approval for its Factor Xa inhibitor. Pfizer also released some better than expected data from ... [Published Motley Fool Discussion Boards - Mar 19 2014]
First reported Mar 19 2014 - Updated Mar 19 2014 - 1 reports

Regular immunization clinic scheduled

The regular monthly immunization clinic will be held Tuesday, March 25 from 1-4 p.m. by appointment only at the Appanoose County Public Health Office at 209 E. Jackson St. in Centerville.Childhood immunizations available include DTaP, Polio, MMR, Varicella, ... [Published Daily Iowegian - Mar 19 2014]

Quotes

...In addition, in a recent article on Forbes , they observe that " The investigators did not explore whether other PDE5A inhibitors, including tadalafil (Cialis) and vardenafil (Levitra), were associated with melanoma, since these drugs were not available at the start of the study. But in their discussion they point out that because these drugs are longer-acting they may potentially result in an even greater increase in risk for melanoma." . It is interesting that we saw a severe price response in Pfizer, with little to no impact on Bayer (OTCPK: BAYRY ) and GlaxoSmithKline GSK ) who manufacture...
Original Article: NEXT ARTICLE More From BioPortfolio on "Pfizer Local Partnership Opens Door To Russia Purchase Of Vaccine"
...Pfizer set up a product facility that it described as the most technologically advanced operation involving a foreign drugmaker in Russia. "It is the only facility for contract production that is of such landmark importance by the amount of local content and sophistication of manufacturing process" remarked Leon Kogan, Pfizer's senior director for business development, adding "it demonstrates Pfizer's seriousness about the Russian market...
...The child was born premature and had suffered from a 'metabolic disorder.' A physician who reviewed the medical record concluded that the child's "developmental regression with chronic encephalopathy following administration of a vaccine is consistent with vaccine induced encephalopathy." A neurologist disagreed and cited a single genetic condition as the cause...

More Content

All (101) | News (87) | Reports (0) | Blogs (13) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Acute bacterial sinusitis risk increased by rhi... [Published Orthopedics Today - Apr 14 2014]
Kevin O’Neill Joins The CECON Group as Program ... [Published Citybizlist - Apr 11 2014]
Pfizer: It Never Rains, It Pours [Published Seeking Alpha - Apr 09 2014]
Shelby County Health Department walk-in childre... [Published Shelby County News - Apr 09 2014]
Kevin O'Neill Joins The CECON Group [Published PRWeb - Apr 08 2014]
This Biotech Market Could Quadruple -- 3 Stocks... [Published Nasdaq - Apr 07 2014]
Proper prior prevention [Published Jerusalem Post - Apr 03 2014]
Patent expiration, stagnant R&D spend seriously... [Published PharmaBiz - Mar 28 2014]
Pfizer Local Partnership Opens Door To Russia P... [Published Health News Daily - Mar 27 2014]
Pfizer Local Partnership Opens Door To Russia P... [Published BioPortfolio - Mar 27 2014]
Parents invited to observe at FPS, register stu... [Published Fredericksburg Standard Post - Mar 27 2014]
Pfizer Touts Local Partnership [Published FirstWord Pharma - Mar 26 2014]
Sanofi bets big on dengue with eyes on a blockb... [Published FierceBiotech - Mar 26 2014]
When is compensation available following a vacc... [Published Press News.org - Mar 26 2014]
Pfizer Inc (NYSE:PFE) | Pfizer Invites Public T... [Published Jutia Group - Mar 25 2014]
'Breakthrough' nod for Pfizer MenB candidate se... [Published FierceVaccines - Mar 25 2014]
Five Star Stock Watch: Pfizer [Published Benzinga.com - Mar 25 2014]
Renaissance Technologies buys a stake in Pfizer... [Published Yahoo! Finance - Mar 24 2014]
Breakthrough Therapy Status for Pfizer's Drug -... [Published Zacks.com - Mar 24 2014]
Breakthrough Therapy Status for Pfizer's Drug [Published Yahoo! Finance - Mar 24 2014]
Recent Trials Could Help Pfizer Solidify Its Do... [Published BioPortfolio - Mar 20 2014]
Recent Trials Could Help Pfizer Solidify Its Do... [Published Trefis - Mar 20 2014]
Pfizer snags a 'breakthrough' tag for its menin... [Published FierceBiotech - Mar 20 2014]
Sanofi launches a vaccine R&D program with bloc... [Published FierceBiotech - Mar 20 2014]
Vaccine Contract Manufacturing Market to Reach ... [Published PharmaAsia - Mar 20 2014]
Why Pfizer's Debt Levels Should Be Of Little Co... [Published BioPortfolio - Mar 19 2014]
Why Pfizer's Debt Levels Should Be Of Little Co... [Published Seeking Alpha - Mar 19 2014]
Mixed News for Pfizer: A Good Chance to Buy? [Published Motley Fool Discussion Boards - Mar 19 2014]
Regular immunization clinic scheduled [Published Daily Iowegian - Mar 19 2014]
Market Update (NYSE:PFE): Pfizer Launches 2013 ... [Published Jutia Group - Mar 18 2014]
1 2 3 4
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Here’s Why Pfizer’s Holding on to Its Celebrex ... [Published Wall St. Cheat Sheet - Mar 13 2014]
Patent expirations continue to be a problem for the United States’ largest pharmaceutical manufacturers. Since Pfizer’s ( NYSE:PFE ) patent for its blockbuster cholesterol medicine Lipitor — which for nearly a decade was the world’s top selling ...
Pfizer Presents Detailed Results From Landmark ... [Published EON Science - Mar 12 2014]
NEW YORK--(EON: Enhanced Online News)--Pfizer Inc. (NYSE:PFE) today presented detailed results of the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA), the landmark study of approximately 85,000 subjects, demonstrating that Prevenar ...
Pfizer Presents Detailed Results From Landmark ... [Published Business Wire Science: Science News - Mar 12 2014]
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today presented detailed results of the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA), the landmark study of approximately 85,000 subjects, demonstrating that Prevenar 13* (pneumococcal ...
Pfizer Presents Detailed Results From Landmark ... [Published Business Wire Health News - Mar 12 2014]
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today presented detailed results of the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA), the landmark study of approximately 85,000 subjects, demonstrating that Prevenar 13* (pneumococcal ...
Research and Markets: Adult and Adolescent Vacc... [Published Business Wire Health News - Mar 07 2014]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/5kqpfs/adult_and) has announced the addition of the "Adult and Adolescent Vaccines Market to 2018 - Promising Novel Candidates in Late-Stage Development and Prevnar ...
1 2 3
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.